Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coagulation factors are a group of plasma proteins essential for the normal process of blood clotting (coagulation) and hemostasis[1][2][3]. Deficiency or dysfunction of one or more coagulation factors leads to bleeding disorders such as hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), and von Willebrand disease. Therapeutic replacement of deficient or dysfunctional coagulation factors is accomplished with plasma, cryoprecipitate, or purified factor concentrates to restore the integrity of the coagulation cascade and achieve hemostasis[5][7]. This mechanism underlies most treatments for acute or chronic bleeding due to congenital or acquired coagulopathies. Coagulation factor transfusions can be associated with safety concerns, particularly with plasma-derived products, including risks of transfusion-transmitted infection, allergic reactions, and thrombosis.
Factor replacement, Enzymatic catalysis of clot formation, Promotion of thrombin generation, Restoration of deficient step in coagulation cascade
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coagulation factor.